


## Alfacalcidol-d<sub>6</sub>

<b>Cat. No.:</b>	HY-15332		
<b>CAS No.:</b>	1641940-94-4		
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>38</sub> D <sub>6</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	406.67		
<b>Target:</b>	VD/VDR		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### BIOLOGICAL ACTIVITY

#### Description

Alfacalcidol-d<sub>6</sub> is the deuterium labeled Alfacalcidol. Alfacalcidol is a non-selective VDR activator.

### REFERENCES

- [1]. Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. *Journal of Bone and Mineral Research*. 15 770.
- [2]. Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. *Rheumatol Int*. 2004 Jul;24(4):189-97.
- [3]. Ivarsen P, Povlsen JV, Christensen KL. Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study. *Scand J Urol Nephrol*. 2012 Jun 25.
- [4]. Rianthavorn P, et al. Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone. *J Pediatr Endocrinol Metab*. 2012;25(3-4):307-12.
- [5]. Ringe JD, Farahmand P, Schacht E. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients. *Rheumatol Int*. 2012 Apr 8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA